Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 3.75% is 61% below its 5-year average of 9.57%, near the low end of its 5-year range (3.53%–19.55%).
As of the fiscal period ended Tuesday, June 30, 2026. 34.03% below its 12-month average of 5.69%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.75%.
DEBT TO ASSETS RATIO
3.75%
DEBT TO ASSETS RATIO AVG TTM
5.69%
DEBT TO ASSETS RATIO AVG 3Y
9.50%
DEBT TO ASSETS RATIO AVG 5Y
9.57%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-34.03%
CURRENT VS 3Y AVG
-60.52%
CURRENT VS 5Y AVG
-60.80%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+4068.37%
vs the sector median at left
Longeveron Inc.
Market Cap
$7.26M
Debt to Assets Ratio
3.75%
TTM Avg
5.69%
3Y Avg
9.50%
5Y Avg
9.57%
Market Cap
$7.29M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.32M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.14M
Debt to Assets Ratio
0.17%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.50M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.91M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.89M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Longeveron Inc. (LGVN) | $7.26M | 3.75% | 5.69% | 9.50% | 9.57% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.29M | 0.00% | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.32M | 0.00% | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.14M | 0.17% | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.50M | 0.02% | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $6.92M | 0.00% | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.91M | 0.11% | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $6.89M | 0.05% | N/A | N/A | N/A |
| Exicure, Inc. (XCUR)vs › | $6.82M | 0.00% | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.71M | 0.00% | N/A | N/A | N/A |
Debt/Assets
3.8%
Debt/Equity
0.06
Current Ratio
2.63
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 3.75% |
| 2026-03-31 | 3.53% |
| 2025-12-31 | 8.03% |
| 2025-09-30 | 6.32% |
| 2025-06-30 | 6.81% |
| 2025-03-31 | 6.21% |
| 2024-12-31 | 5.66% |
| 2024-09-30 | 5.35% |
| 2024-06-30 | 9.01% |
| 2024-03-31 | 19.55% |
| 2023-12-31 | 16.90% |
| 2023-09-30 | 18.80% |
| 2023-06-30 | 13.61% |
| 2023-03-31 | 11.31% |
| 2022-12-31 | 9.50% |
| 2022-09-30 | 8.99% |
| 2022-06-30 | 8.14% |
| 2022-03-31 | 7.68% |
| 2021-12-31 | 7.35% |
| 2021-09-30 | 12.60% |
| 2021-06-30 | 11.89% |
| 2021-03-31 | 11.40% |
| 2020-12-31 | 44.82% |
| 2020-09-30 | 43.64% |
| 2019-12-31 | 39.10% |
